<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Zhang T</submitter><pubmed_abstract>Besides its mitochondria-based anti-apoptotic role, Bcl-xL also travels to the nucleus to promote cancer metastasis by upregulating global histone H3 trimethyl Lys4 (H3K4me3) and TGFβ transcription. How Bcl-xL is translocated into the nucleus and how nuclear Bcl-xL regulates H3K4me3 modification are not understood. Here, we report that C-terminal Binding Protein 2 (CtBP2) binds Bcl-xL via its N-terminus and translocates Bcl-xL into the nucleus. Knockdown of CtBP2 by shRNA decreases the nuclear portion of Bcl-xL and reverses Bcl-xL-induced cell migration and metastasis in mouse models. Furthermore, knockout of CtBP2 suppresses Bcl-xL transcription. The binding between Bcl-xL and CtBP2 is required for their interaction with MLL1, a histone H3K4 methyltransferase. Pharmacologic inhibition of </pubmed_abstract><journal>bioRxiv : the preprint server for biology</journal><pagination>2023.04.26.538373</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10168309</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Bcl-xL is translocated to the nucleus via CtBP2 to epigenetically promote metastasis.</pubmed_title><pmcid>PMC10168309</pmcid><pubmed_authors>Grossman SR</pubmed_authors><pubmed_authors>Tan YA</pubmed_authors><pubmed_authors>Wang D</pubmed_authors><pubmed_authors>Choi S</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Zhang T</pubmed_authors><pubmed_authors>Li S</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Mishra B</pubmed_authors><pubmed_authors>Chen YT</pubmed_authors><pubmed_authors>Jiang X</pubmed_authors><pubmed_authors>Du YN</pubmed_authors><pubmed_authors>Damle P</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Na JH</pubmed_authors><pubmed_authors>Xiang JZ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Bcl-xL is translocated to the nucleus via CtBP2 to epigenetically promote metastasis.</name><description>Besides its mitochondria-based anti-apoptotic role, Bcl-xL also travels to the nucleus to promote cancer metastasis by upregulating global histone H3 trimethyl Lys4 (H3K4me3) and TGFβ transcription. How Bcl-xL is translocated into the nucleus and how nuclear Bcl-xL regulates H3K4me3 modification are not understood. Here, we report that C-terminal Binding Protein 2 (CtBP2) binds Bcl-xL via its N-terminus and translocates Bcl-xL into the nucleus. Knockdown of CtBP2 by shRNA decreases the nuclear portion of Bcl-xL and reverses Bcl-xL-induced cell migration and metastasis in mouse models. Furthermore, knockout of CtBP2 suppresses Bcl-xL transcription. The binding between Bcl-xL and CtBP2 is required for their interaction with MLL1, a histone H3K4 methyltransferase. Pharmacologic inhibition of </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2025-04-04T13:07:19.418Z</modification><creation>2025-04-04T13:07:19.418Z</creation></dates><accession>S-EPMC10168309</accession><cross_references><pubmed>37163116</pubmed><doi>10.1101/2023.04.26.538373</doi></cross_references></HashMap>